(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 9 January 2003 (09.01.2003)

PCT

(10) International Publication Number WO 03/002530 A3

(51) International Patent Classification⁷: C07D 207/16, 277/06, A61K 31/40, 31/426, A61P 3/10

(21) International Application Number: PCT/US02/20466

(22) International Filing Date: 26 June 2002 (26.06.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/301,333 60/387,011 27 June 2001 (27.06.2001) US 6 June 2002 (06.06.2002) US

6 June 2002 (06.06.2002) U

(71) Applicant (for all designated States except US):

SMITHKLINE BEECHAM CORPORATION

[US/US]; One Franklin Plaza, Philadelphia, PA 19101

(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HAFFNER, Curt, Dale [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). MC-DOUGALD, Darryl, Lynn [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). RANDHAWA, Amarjit, Sab [CA/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). REISTER, Steven, Michael [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). DEATON, David, N. [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). DEATON, David, N. [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park,

NC 27709 (US). LENHARD, James, Martin [US/US]; GlaxoSmithKline, Five Moore Drive, Po Box 13398, Research Triangle Park, NC 27709 (US).

- (74) Agents: LEVY, David, J et al.; GlaxoSmtihKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report


(88) Date of publication of the international search report: 3 April 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

4

(54) Title: PYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS





(57) Abstract: The present invention relates to novel compounds of formula (I):, their use for inhibiting serine proteases, such as dipeptidyl peptidases, such as dipeptidyl peptidase IV (DPP-IV) and to methods for their production and their therapeutic utility.

Ir tional Application No PCT/US 02/20466

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D207/16 C07D A61K31/426 A61P3/10 C07D277/06 A61K31/40 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) CO7D A61K A61P IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages 1,13,14, ASHWORTH D M ET AL: "4-Cyanothiazolidides X 16,20 as very potent, stable inhibitors of dipeptidyl peptidase IV" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 22, 19 November 1996 (1996-11-19), pages 2745-2748, XP004135888 ISSN: 0960-894X examples 3,6,7,9examples 13-15; table II abstract Patent family members are listed in annex. Further documents are listed in the continuation of box C. "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search **15**. 01. 2003 16 December 2001 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Seitner, I

0.45		PC1/US 02/20466
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 15309 A (FERRING BV ; JENKINS PAUL D (GB); JONES D MICHAEL (GB); SZELKE MICH) 8 June 1995 (1995+06-08) cited in the application examples 19-23,27-29; table 2 tables 1-9 claims 2-5	1,13,14, 16,20
P,X	WO 01 81304 A (EVANS DAVID MICHAEL; PITT GARY ROBERT WILLIAM (GB); FERRING BV (NL) 1 November 2001 (2001-11-01) examples 20,21; table 1 examples 167,168; table 2 examples 263,264; table 3 examples 269,270; table 4 examples 335,336; table 5 examples 399,400; table 6 examples 1,2,4,7-9,12 tables 1-7 claims, 22-26	1,16,20
P,X	WO 01 81337 A (EVANS DAVID MICHAEL ;PITT GARY ROBERT WILLIAM (GB); FERRING BV (NL) 1 November 2001 (2001-11-01) examples 1-3,6,10,11 example 16; table 1 example 38; table 2 tables 1,2 claims 9-15	1,16,20
A	AUGUSTYNS K ET AL: "THE UNIQUE PROPERTIES OF DIPEPTIDYL-PEPTIDASE IV (DPP IV/CD26) AND THE THERAPEUTIC POTENTIAL OF DPP IV INHIBITORS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 4, 1999, pages 311-327, XP000870290 ISSN: 0929-8673 abstract; examples 3-9	1,16,20
E	EP 1 245 568 A (SERVIER LAB) 2 October 2002 (2002-10-02) examples 44,45,54,55,61,64,74,76 claims 12-14	1,16,20

C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X '	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KITASHIMA, HIROSHI ET AL: "Preparation of N-(.alphaaminoacyl)-2-cyanopyrrolidine derivatives as inhibitors of dipeptidyl peptidase IV (DPP-IV) for drugs" retrieved from STN Database accession no. 137:232910 XP002224329 CAS RN: 459834-87-8; 459834-89-0; 459834-90-3; 459834-91-4; 459834-92-5; 459834-93-6; 459834-94-7; 459834-95-8; 459834-96-9; 459534-97-0; 459834-98-1; 459834-99-2; 459835-00-8; 459835-01-9; 459835-02-0; 459835-03-1; 459835-04-2; 459835-05-3; 459835-06-4; 459835-08-6;	1,16,20
E	459835-10-0 abstract -& JP 2002 265439 A (MITSUBISHI WELL PHARMA K. K., JAPAN) 18 September 2002 (2002-09-18) page 21 -page 23	1,16,20
E .	WO 02 53169 A (KEYNEUROTEK AG I.G.) 11 July 2002 (2002-07-11) claims 2,8	1,16,20
Р,Х	WO 01 89569 A (ANSORGE SIEGFRIED; ARNDT MARCO (DE); LENDECKEL UWE (DE); NEUBERT K) 29 November 2001 (2001-11-29) claims 4,10	1,16,20
Х	WO 01 40180 A (EVANS DAVID MICHAEL ;FERRING BV (NL)) 7 June 2001 (2001-06-07) page 19, line 3 page 20, line 3 page 25, line 17 page 26, line 10 page 27, line 3 page 28, line 3 page 32, line 3 page 33, line 3	1
X	JIANG J D ET AL: "Inhibition of uman immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors" RESEARCH IN VIROLOGY, ELSEVIER, PARIS, FR, vol. 4, no. 148, 1 July 1997 (1997-07-01), pages 255-266, XPO02074032	1,16,20
	ISSN: 0923-2516 the whole document figure 1	

		FC17U3 U2/2U400
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LI J ET AL: "AMINOACYLPYRROLIDINE-2-NITRILES: POTENT AND STABLE INHIBITORS OF DEIPEPTIDYL-PEPTIDASE 4 (CD 26)" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, vol. 323, no. 1, October 1995 (1995-10), pages 148-154, XP000965067 ISSN: 0003-9861 the whole document	1,16,20
X	LOREY S ET AL: "NEW FLUOROGENIC DIPEPTIDYL PEPTIDASE IV/CD26 SUBSTRATES AND INHIBITORS" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 421, 1997, pages 157-160, XP001008342 ISSN: 0065-2598 table 2	1,16,20
X	EP 0 933 379 A (SHIONOGI & CO) 4 August 1999 (1999-08-04) page 54, line 24	1
X	WO 00 56297 A (BROQUA PIERRE ;FERRING BV (NL)) 28 September 2000 (2000-09-28) examples 1A,1B, claim 1	1,16,20
X	STOECKEL-MASCHEK A ET AL: "POTENT INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR MECHANISMS OF INHIBITION" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 477, 2000, pages 117-123, XP008000943 ISSN: 0065-2598 figure 3 tables 1,2	1,16,20

International application No. PCT/US 02/20466

INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inter	national Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
.1. 🗶	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 18-24 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
لـــا	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
١	
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inter	mational Searching Authority found multiple Inventions in this international application, as follows:
,	see additional sheet
1. X	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-4 (all partially); 5,6,11,
12 (all completely); 13-33 (all partially)

Compounds according to formula (I) of claim 1 in which X represents -S(0)b- as well as their pharmaceutical use and compositions.

2. Claims: 1-4 (all partially); 7-10 (all completely); 13-33 (all partially)

Compounds according to formula (I) of claim 1 in which X represents -CH2- as well as their pharmaceutical use and compositions.

Information on patent family members

						13 02/20400
	atent document d in search report		Publication date		Patent family member(s)	Publication date
WO	9515309	Α	08-06-1995	AU	1113395 A	19-06-1995
				AU	8421998 A	12-11-1998
	•	•		CA	2178066 A1	08-06-1995
	•		i	CN	1141033 A ,E	
				CZ	9601595 A3	15-01-1997
				EP	0731789 A1	18-09-1996
				FI	962315 A	05-08-1996
				WO	9515309 A1	08-06-1995
				HU	76274 A2	28-07-1997
			1	JP	9509921 T	07-10-1997
				NO	962269 A	30-07-1996
				PL	314838 A1	30-09-1996
				RU	2156237 C2	20-09-2000
			•	TW	397811 B	11-07-2000
				US	6201132 'B1	13-03-2001
	•			US	5939560 A	17-08-1999
				ZA	9409525 A	02-08-1995
WO	0181304	Α	01-11-2001	AU	5054401 A	07-11-2001
				WO	0181304 A1	01-11-2001
WO	0181337	Α	01-11-2001	 AU	5053701 A	07-11-2001
		1		WO	0181337 A1	01-11-2001
EP	1245568	Α,	02-10-2002	FR	2822826 A1	04-10-2002
•		-1	-	AU	2935002 A	03-10-2002
	1			CN	1377879 A	06-11-2002
				EP	1245568 A1	02-10-2002
				NO	20021542 A	30-09-2002
				PL	353084 A1	07-10-2002
JP	2002265439	A	18-09-2002	NONE		
WO	0253169	A	11-07-2002	DE .	10100053 A1	22-08-2002
				WÖ	02053169 A2	11-07-2002
WO	0189569	Α	29-11-2001	DE	10025464 A1	06-12-2001
		•		AU	6747501 A	03-12-2001
				WO	0189569 A1	29-11-2001
WO	0140180	 А	07-06-2001	 AU	1538401 A	12-06-2001
		٠.		BR	0015788 A	16-07-2002
				CZ	20021520 A3	16-10-2002
				WO	0140180 A2	07-06-2001
				NO	20022502 A	27-05-2002
EP	0933379	 А	04-08-1999	AU	713133 B2	25-11-1999
	10000,0		04 00 1333	AU	3868097 A	19-03-1998
				BR	9712081 A	24-08-1999
				EP	0933379 A1	04-08-1999
				JP	3234236 B2	04-08-1999
				US		
					6319902 B1	20-11-2001
				CN	1235610 A	17-11-1999
				MO	9808867 Al	05-03-1998
				KR	2000035930 A	26-06-2000
				TR	9900477 T2	21-06-1999
		Α	**	AU	3318600 A	09-10-2000

Information on patent family members

International Application No PCT/US 02/20466

WO 0056297 A CN 1359293 T 17-07-2002 CZ 20013411 A3 17-04-2002 EP 1171121 A2 16-01-2002 HU 0200391 A2 29-06-2002 WO 0056297 A2 28-09-2000 NO 20014608 A 31-10-2001 NZ 514450 A 26-11-2002 TR 200102648 T2 21-12-2001	Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
TK 200102040 12 21-12-2001	WO 0056297			CZ EP HU WO NO	20013411 A3 1171121 A2 0200391 A2 0056297 A2 20014608 A	17-04-2002 16-01-2002 29-06-2002 28-09-2000 31-10-2001	

Form PCT/ISA/210 (patent family annex) (July 1992)